Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 3:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Clinically Significant Portal Hypertension Clear all

Completed Phase 2 Interventional Results available

The Effect of Sorafenib on Portal Pressure

NCT01714609

View directory record Official record

Conditions: Clinically Significant Portal Hypertension
Interventions: Placebo, Sorafenib; Drug
Lead sponsor: Yale University; Other
Eligibility: 20 Years to 75 Years

Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Dec 28, 2020 · Synced May 22, 2026, 3:48 AM EDT

Terminated Phase 2 Interventional Results available

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

NCT06082843

View directory record Official record

Conditions: Hypertension, Portal, Liver Cirrhosis
Interventions: Placebo, Avenciguat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Pasadena, California • Rialto, California

Source: ClinicalTrials.gov public record

Updated Jun 11, 2025 · Synced May 22, 2026, 3:48 AM EDT

Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05282121

View directory record Official record

Conditions: Liver Diseases, Hypertension, Portal
Interventions: Avenciguat, Empagliflozin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more

Source: ClinicalTrials.gov public record

Updated Sep 3, 2025 · Synced May 22, 2026, 3:48 AM EDT

Completed No phase listed Observational Accepts healthy volunteers

Assessment of Portal Hypertension With Multiparametric MRI

NCT03436550

View directory record Official record

Conditions: Portal Hypertension, Clinically Significant Portal Hypertension
Interventions: mpMRI, ARFI US; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older

Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Mar 5, 2023 · Synced May 22, 2026, 3:48 AM EDT

Recruiting Phase 4 Interventional

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

NCT07058155

View directory record Official record

Conditions: Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program; Procedure · Drug · Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years

Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Cleveland, Ohio

Source: ClinicalTrials.gov public record

Updated Dec 22, 2025 · Synced May 22, 2026, 3:48 AM EDT

Terminated Phase 2 Interventional Results available

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05161481

View directory record Official record

Conditions: Hypertension, Portal
Interventions: Avenciguat (BI 685509), Placebo matching Avenciguat (BI 685509); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Pasadena, California • Rialto, California • Miami Lakes, Florida + 3 more

Source: ClinicalTrials.gov public record

Updated Sep 2, 2025 · Synced May 22, 2026, 3:48 AM EDT